ANZCTR search results

Relative Energy Deficiency in Sport (REDs) is a condition that can occur when athletes do not consume enough energy to support their training and the body's normal functions. REDs can affect health, performance, recovery, hormones, and bone health. This study will evaluate and compare a range of existing and emerging tools used to identify athletes at risk of REDs. Participants will complete questionnaires, dietary assessments, body composition measurements, blood tests, imaging scans, and physical performance assessments during a single study visit. The findings will help determine which tools are most useful for accurately identifying REDs in athletes.

In this study we will record on video laparoscopic gastric bypass procedures whilst using a new laparoscopic instrument holder, Surgirack. This device has been approved by the Therapeutic Goods Administration (TGA) which is the Australian government organisation tasked with making sure medical devices are safe. Surgirack has been used since January 2025 over 3000 times across 10 different hospitals and by 45 different surgeons within Adelaide. Surgirack has been used in laparoscopic gastric bypass close to 200 times since January 2025. We will also record laparoscopic gastric bypass using standard instrument holders. We will then compare the videos to see if there is a difference in instrument exchange time between the two different instrument holders. We believe that instrument exchange time is significantly reduced which would then reduce operating time.

This study will compare a needle-free device (J-Tip®) with standard care (topical numbing cream) in children aged 8-18 years requiring IV cannulation. The aim is to determine whether a larger trial is feasible by assessing recruitment, study processes, safety, and acceptability. Children's pain during cannulation will also be measured to inform a future trial testing whether the J-Tip® reduces pain.

The purpose of this research project is to determine whether treatment with semaglutide may help maintain control of psoriasis and reduce the risk of relapse after stopping biologic therapy in people with chronic plaque psoriasis (CPP) who are overweight or living with obesity. The study will also examine whether semaglutide improves weight and metabolic health. Participants will receive semaglutide and will be monitored over 12 months following discontinuation of biologic therapy to assess relapse rates, weight change, metabolic health, quality of life and inflmmatory markers in blood and skin. Participation in this study involves the following three phases: Screening, Treatment, and Study Completion (no additional follow-up after 12 months). In the treatment phase, participants will commence once-weekly subcutaneous semaglutide injections beginning at 0.25 mg and gradually increasing to 2.4 mg per week over 16 weeks. During the dose escalation phase, participants will need to attend clinic monthly, then every 8-10 weeks during the maintenance phase. The trial will involve weight, waist circumfrence and blood pressure measurements, blood samples, physical examinations and quality of life questionnaires.

Chronic suppurative otitis media (CSOM) is the most severe form of middle ear disease, characterised by a hole in the eardrum, though which discharge drains (for longer than two weeks). CSOM disproportionally impacts children living in low socioeconomic conditions, including remote-living First Nations children. This trial will compare topical hydrogen peroxide followed by topical ciprofloxacin with ciprofloxacin alone to manage CSOM that has failed to resolve with standard treatment.

- This study is testing a new medicine called IDB-1829 for advanced prostate cancer that no longer responds to standard hormone treatments. Who is it for? - You may be eligible for this study if you are an adult with prostate cancer, where the cancer has stopped responding to hormone therapy. Participants in this study must have also received at least one prior treatment for resistant prostate cancer. Study details - All participants in this study will be asked to take a dose of the new medicine daily in 21-day cycles. The number of cycles will depend on how the participant is responding to the treatment. - Participants will also be asked to provide blood samples throughout the treatment and be followed up for review of safety and via scans to assess changes in the cancer. - It is hoped that this research will help determine if the new medicine is a viable option for the treatment of hormone resistant prostate cancer.

This study is testing a new medicine called IDB-1829 for advanced prostate cancer that no longer responds to standard hormone treatments. Who is it for? You may be eligible for this study if you are an adult with prostate cancer, where the cancer has stopped responding to hormone therapy. Participants in this study must have also received at least one prior treatment for resistant prostate cancer. Study details All participants in this study will be asked to take a dose of the new medicine daily in 21 day cycles. The number of cycles will depend on how the participant is responding to the treatment. Participants will also be asked to provide blood samples throughout the treatment, and be followed up for review of safety and via scans to assess changes in the cancer. It is hoped that this research will help determine if the new medicine is a viable option for the treatment of hormone resistant prostate cancer.

This pilot study is aiming to evaluate the effect of Reiki on pain, anxiety and patient experience in people living with cancer Who is it for? You may be eligible to join this study if you are aged 18 years or above, have been diagnosed with cancer (stage I – III) and experiencing cancer-related pain and/or anxiety. You also need to be English-speaking, sufficient to complete the survey, able to provide informed consent and be clinically stable at the time of participation. Study details All participants will receive a once-off free 30 min Reiki therapy session with a professional Reiki practitioner in the practitioner’s private practice. Participants will complete surveys at before and after the session to determine changes in anxiety, pain, wellbeing and experiences with Reiki therapy. This study will provide preliminary evidence to inform future research on Reiki as a supportive therapy for improving wellbeing among people living with cancer.

Previous research has shown that eye symptoms are commonly experienced by bush firefighters during work and current official recommendations for protective eyewear have limitations for use on the fireground. The research study aims to determine whether commercially available eyecare products can reduce the adverse effects of bushfire smoke on the eyes of Australia bush firefighters while they are working. In this study, bush firefighters will be divided into 4 groups and with each group randomly allocated to receive a commerically available eyecare product to use at one fireground shift. The products are eyedrops, eyelid wipes and saline to rinse eyes. Change in eye symptoms and signs of eye surface problems will be measured before and after use of the products to determine effectivity.

This study is a pilot, mixed-methods evaluation of the Mia AI platform for Late-Onset Pompe Disease (LOPD). It aims to assess the usability, acceptability, and perceived clinical utility of an AI-driven decision-support system that assists with patient identification, biomarker monitoring, and multidisciplinary care coordination. Approximately 30 participants will be recruited, including patients with LOPD, carers, clinicians, allied health professionals, and researchers. Participants will complete one 60–90 minute session involving interaction with the Mia AI system, a System Usability Scale questionnaire, and a semi-structured interview exploring their experiences and views on AI in Pompe disease care. In parallel, the research team will independently evaluate the technical performance of the system using established AI assessment frameworks.